Peptide-Drug Conjugates in Precision Oncology: Engineering Next-Generation Targeted Therapies

Authors

Keykavous Parang, Chapman UniversityFollow
Thuy Do, Chapman University
Clare Dinh, Chapman University
Mahsa Moazen, Chapman University
Troy Khong, Chapman University

Document Type

Article

Publication Date

2025

Abstract

Peptide-drug conjugates (PDCs) offer a revolutionary approach to cancer therapy by combining tumor-homing peptides, cleavable linkers, and cytotoxic payloads. This article explores their design, therapeutic advantages, and emerging applications, highlighting how precision bioengineering is shaping safer, more selective, and scalable oncologic treatments beyond antibody-drug conjugates.

Comments

This article was originally published in Pharma Focus Asia in 2025.

Recommended Citation

Parang K, Do T, Dinh C, Moazen M, Khong T. Peptide-drug conjugates in precision oncology: Engineering next-generation targeted therapies. Pharma Focus Asia. 2025. https://www.pharmafocusasia.com/articles/peptide-drug-conjugates-in-precision-oncology

Copyright

Ochre Media Pvt. Ltd.